Clinical Trials Directory

Trials / Unknown

UnknownNCT03963700

Tumor Characteristics in Patients With Paraneoplastic Neurological Syndromes (PNS)

Genomic Profile and Tumor Immune Attack in Paraneoplastic Neurological Syndromes (PNS)

Status
Unknown
Phase
Study type
Observational
Enrollment
980 (estimated)
Sponsor
Hospices Civils de Lyon · Academic / Other
Sex
All
Age
18 Years – 100 Years
Healthy volunteers
Not accepted

Summary

Paraneoplastic neurological syndromes (PNS) are immune-mediated complications of cancer that can affect any part of the central or peripheral nervous system. PNS occurs at the intersection between immune system and the tumor, where a combination of genetical and environmental factors may play a role. Mechanisms leading to immune tolerance breakdown and autoimmunity in PNS remain largely unknown, and this reflects in an unsatisfactory repertoire of treatments available. Moreover, a better understanding of the biological mechanisms underlying PNS would allow a more precise identification of the modalities that permit PNS patients to have a better oncological prognosis than cancer patient without PNS, with obvious repercussions in clinical oncology. To this effect, an extremely innovative approach involves directly exploring the tumoral tissue of patients suffering from specific PNS via genomic and transcriptomic analysis. The study team hypothesizes that antigen ectopic expression by tumour cells may contribute to the generation of PNS. In the present study, the investigators will analyze the salient features of tumors associated with PNS, namely the histological and immune cells infiltrate characteristics, their transcriptomic profile, and mutational status of involved antigens.

Conditions

Timeline

Start date
2019-02-01
Primary completion
2022-01-01
Completion
2022-01-01
First posted
2019-05-28
Last updated
2019-05-30

Locations

1 site across 1 country: France

Source: ClinicalTrials.gov record NCT03963700. Inclusion in this directory is not an endorsement.